Role of erbB2 in breast cancer chemosensitivity

BioEssays

Volumn 22, Issue 7, 2000, Pages 873-680

  Yu, Dihua ^a   Hung, Mien Chie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PACLITAXEL; RETINOIC ACID; TRASTUZUMAB;

BREAST TUMOR; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; PROTO ONCOGENE; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENES, ERBB-2; HUMANS; PACLITAXEL; TRETINOIN;

EID: 0034222135     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-1878(200007)22:7<673::aid-bies10>3.0.co;2-a     Document Type: Review

References (67)

1. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor. Nature 1986;319: 230-234.
2. Bargmann CI, Hung M-C, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986;319: 226-230.
3. Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232:1644-1646.
4. Coussens L, Yang-Feng TL, Liao Y-C, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke Y. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-1139.
5. Stern DF, Heffernan PA, Weinberg RA. p185, a product of the neu protooncogene, is a receptor-like protein associated with tyrosine kinase activity. Mol Cell Biol 1986;6:1729-1740.
6. C-neu density govern receptor interactions and tyrosine kinase activation. Proc Natl Acad Sci USA 1994;91:1711-1715.
7. Carraway III KL, Rossi EA, Komatsu M, Komatsu M, Price-Schiavi SA, Huang D, Guy PM, Carvajal ME, Fregien N, Carraway CA, Carraway KL. An intramembrane modulator of the erbB2 receptor tyrosine kinase that potentiates neuregulin signaling. J Biol Chem 1999;274:5263-5266.
8. Carraway KL 3rd, Sliwkowski MX, Akita R, Platko JV, Guy PM, Nuijens A, Diamonti AJ, Vandlen RL, Cantley LC, Cerione RA. The erbB-3 gene product is a receptor for heregulin. J Biol Chem 1994;269: 14303-14306.
9. erbB-4. Nature 1993;366:473-475.
10. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-1655.
11. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
12. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989;244: 707-712.
13. Yu D, Hung M-C. HER-2/neu gene in human cancers. In: Freireich E, Stass SA, eds. Molecular Basis of Oncology. Vol. 5. Cambridge: Blackwell Scientific Publications Inc., 1995:p131-162.
14. Berchuck A, Kamel A, Whitaker R, Kerns B. Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-4091.
15. Tauchi K, Hori S, Itoh H, Osamura RY, Tokuda Y, Tajima T. Immunohistochemical studies on oncogene products (c-erbB-2 EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions: with special reference to their prognostic significance in carcinoma. Virchows Arch. A Pathol Anat Histopathol 1989;416:65-73.
16. Lacroix H, Iglehart JD, Skinner MA, Kraus MH. Overexpression of erbB-2 or EGF-receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastasis Oncogene 1989;4:145-151.
17. van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R. Neu-protein overexpression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-1245.
18. Yu D, Wolf JK, Scanlon M, Price JE, Hung M-C. Enhanced c-ertB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 1993;53: 891-898.
19. Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastatic potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 1997;57:1199-1205.
20. Rozan S, Vincent-Salomon A, Zafrani B, Validire P, De Cremoux P, Bernoux A, Nieruchalski M, Fourquet A, Clough K Dieras V, Pouillart P, Satre-Garau X. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 1998;79:27-33.
21. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Samon DJ. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-2671
22. Dickman S. Antibodies stage a comeback in cancer treatment Science 1998;280:1196-1197.
23. Yu D, Suen T-C, Yan D-H, Chang LS, Hung M-C. Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci USA 1990;87:4499-4503
24. Yu D, Matin A, Xia W, Sorgi F, Huang L, Hung M-C. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene 1995;11:1383-1388.
25. Zhang Y, Yu D, Xia W, Hung M-C. HER-2/neu-targeting cancer therapy via adenovirus-med ated E1A delivery in an animal model. Oncogene 1995;10:1947-1954.
26. Zhang Y, Xia W, Shao R, et al. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. Oncogene 1997;14:561-568.
27. Hortobagyi GN, Ueno NT, Xia W. Cationic liposome-mediated adenovirus type 5 E1A gene transfer to human breast and ovarian cancer cells and its biological effects: A phase I clinical trial. Nature Medicine 2000;:submitted.
28. Deshane J, Grim J, Loechel S, Siegal GP, Alvarez RD, Curiel DT. Intracellular antibody against erbB-2 mediates targeted tumor cell eracication by apoptosis. Cancer Gene Ther 1996;3:89-98.
29. Zhang L, Chang CJ Bacus SS, Hung M-C. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. Cancer Res 1995;55:3890-3896.
30. Hayes DF, Henderson IC, Snap ro CL. Treatment of metastatic breast cancer: present and future prospects. Seminars in Oncol 1995;22:5-21.
31. Gusterson BA, Gelber RD, Goldhirsch A, Price KN. Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992; 10:1049-1056.
32. Jarv nen TA, Holli K, Kuukasjarvi T, Isola JJ Predictive value of topoisomerase II alpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J.Cancer 1998;77 2267-2273.
33. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M. C-erbB-2 expression and response to adjuvant therapy in woman with node-positive early breast cancer. N Engl J Med 1994;330:1260-1266.
34. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 994;73:2359-2365.
35. Fehm T, Ma monis P, Weitz S, Teramoto Y, Katalinic A, Jager W. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 1997;43:87-95.
36. Mehta RR, McDermott JH, Hieken TJ, Marier KC, Patel MK, Wild LD. Plasma c-erbB2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. J Clin Oncol 1998;16: 2409-2416.
37. Fehm T, Maimonis P, Katalinic A, Jager WH. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology 1998; 55:33-38.
38. mdr-1 renders breast cancer cells highly resistant to Taxol. Oncogene 1998;16: 2087-2094.
39. Yu D, Liu B, Tan M, Li J, Wang S-S, Hung M-C. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996;13 1359-1365.
40. R) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58: 2825-2831.
41. Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991;51: 4575-4580.
42. Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast cancer and ovarian cancer cells. Oncogene 1994;9: 1829-1838.
43. Arteaga CL, Winnier AR, Poirier MC, Lopez-Larraza DM, Shawver LK, Hurd SD, Stewart SJ. p185c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res 1994;54:3758-3765.
44. Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 1998; 17:2235-2249.
45. Jacquemier J, Penault-Llorca F, Viens P, et al. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. Anticancer Res 1994;14:2773-2778.
46. Porter-Jordan K, Lippman ME. Overview of the biologic markers of breast cancer. Breast Cancer 1994;8:73-100.
47. Niskanen E, Blomqvist C, Franssila K, Hietanen P, Wasenius VM. Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br J Cancer 1997;76: 917-922.
48. Ross J, S, et al. The HER-2/neu oncogene in breast cancer prognostic factor, predictive 'actor and target for therapy. The Oncologist 1998; 3:237-252.
49. Pegram MD, Finn RS, Arzoo K, Beryt M, Pietras RJ, Slamon DJ. The effect of HER2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997;15: 537-547.
50. Alaoui-Jamali MA, Paterson J, Al Moustafa AE, Yen L. The role of erbB-2 tyrosine kinase receptor in cellular intrinsic chemoresistance: mechanisms and implications. Biochem Cell Biol 1997;75:315-325.
51. Cdc2 kinase. Mol Cell 1998;2:581-591.
52. Shepard HM, Lewis GD, Sarup JC Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Paladino MA Jr, Ulrich A Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic. J Clin Immunol 1992;11:117-127.
53. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185her2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-744.
54. Yu D, Scorsone K, Hung M-C. Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene. Mol Cell Biol 1991;11:1745-1750.
55. Yu DH, Hamada JI, Zhang H, Nicolson GL, Hung M-C. Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. Oncogene 1992;7: 2263-2270.
56. Ueno NT, Yu D, Hung MC. Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxol (Taxol) by adenovirus type 5 E1A Oncogene 1997;15:953-960.
57. Chen H, Yu D, Chinnadurai G, Karunagaran D, Hung M. Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu. Oncogene 1997;14: 1965-1971.
58. Zhang L, Lau YK, Xia W, Hortobagyi GN, Hung MC. Tyros ne kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel. Clin Cancer Res 1999;5:343-353.
59. neu. Clin Cancer Res 1999; In Press.
60. Huston JS, McCartney J, Tai MS, Mottola-Hartshorn C, Jin D, Warren F, Keck P, Oppermann H. Medical applications of single-chain antibodies. Int Rev Immunol 1993;10:195-217.
61. Haynes NM, Smyth MJ, Kershaw MH, Trapani JA, Darcy PK. Fas-ligand-mediated lysis of erbB-2-overexpressing tumour cells by redirected cytotoxic T lymphocytes. Cancer Immunol Immunother 1999;47: 278-286.
62. Barnes MN, Deshane JS, Siegal GP, Alvarez RD, Curiel DT. Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity. Clin Cancer Res 1996;2:1089-1095.
63. Wright M, Grim J, Deshane J, Kim M, Strong TV, Siegal GP, Curiel DT. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2. Gene Ther 1997; 4:317-322.
64. Grunt T, Dittrich E, Ofterdinger M, Schneider SM, Dittrich C, Huber H. Effects of retinoic acid and fenretinide on the c-erbB-2 expression, growth and cisplatin sensitivity of breast cancer cells. Br J Cancer 1998; 78:79-87.
65. Giannois J, Ioannidou-Mouzaka L. Molecular aspects of breast and ovarian cancer. Eur J Gynaecol Oncol 1997;18:387-393.
66. Fisher DE. Apoptosis in career therapy: crossing the threshold. Cell 1994;78:539-542.
67. Harris LN, Yang L Tang C, Yang D, Lupu R. Induction of sensitivity to doxorubicin and etoposide by translection of MCF-7 breast cancer cells with heregulin beta-2. Clin Cancer Res 1998;4:1005-1012.